Products

4SC develops targeted small molecule drugs for the treatment of cancer in indications with a high unmet medical need. In doing so, we wish to offer affected patients treatment options that are more effective and better tolerated to provide a better quality of life.

The core 4SC product pipeline currently comprises two compounds in clinical development, resminostat and 4SC-202, and a third molecule, 4SC-208, that is in pre-clinical development.

Resminostat

Resminostat is an orally administered histone deacetylase (HDAC) inhibitor with an innovative epigenetic mechanism of action that potentially represents a novel therapy for a broad spectrum of oncology indications, both in monotherapy and particularly in combination with other anti-cancer drugs.

Learn more about resminostat

4SC-202

4SC-202 is an orally administered small molecule for the treatment of cancer. The compound is an epigenetic modulator with a unique mechanism of action that inhibits the enzymes lysine-specific demethylase 1 (LSD1) and histone deacetylase (HDAC) 1, 2, 3, which are believed to play significant roles in the regulation of aberrant cancer signaling pathways.

Learn more about 4SC-202

4SC-208

4SC-208 is a small molecule specifically targeting two kinases crucial for Hedgehog/GLI signaling. Inhibition of the Hedgehog/GLI pathway has emerged as a highly effective strategy in obstructing the tumorigenic capacity of cancer stem cells, responsible for metastasis and recurrence of tumors.

Learn more about 4SC-208

Out-licensed products

4SC is focused on developing targeted small molecule drugs with an epigenetic mode of action for the treatment of cancer. 4SC has out-licensed further products to national and international pharma and biotech companies.

Assets available for out-licensing

4SC is focused on developing targeted small molecule drugs with an epigenetic mode of action for the treatment of cancer. Further assets are available for partnering or out-licensing.

More information on these assets are available email hidden; JavaScript is required.

Share this page:

Follow us on: